Zikani Therapeutics is an emerging leader in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) as therapeutics for people with limited treatment options. Zikani's TURBO-ZMTM platform allows rapid synthesis of novel compounds that can be optimized to modulate the ribosome in a disease specific manner. As the company evolves its focus from early-stage to clinical-stage research, Zikani is actively moving into pre-clinical development to target select rare diseases including inherited diseases and cancers caused by nonsense mutations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/21/20 | $7,500,000 | Series A-1 |
Advent Life Sciences Gurnet Point Capital Roche Venture Fund | undisclosed |
